TrialAcute Hip Fracture Study in Patients 65 Years or Greater
Trial details
- Registry ID
- NCT02578095
- Phase
- Phase 2
VKTX
Viking Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095 | VKTX | Phase 2 | Completed | 2017-11-15Actual |
| A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHNCT04173065 | VKTX | Phase 2 | Completed | 2023-05-15Actual |
| VK2735 for Weight Management Phase 2NCT06068946 | VKTX | Phase 2 | Completed | 2024-02-27Actual |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055 | VKTX | Phase 2 | Completed | 2025-06-24Actual |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 | VKTX | Phase 3 | Active not recruiting | 2027-07-01Estimated |
| VK2735 for Weight Management Phase 3NCT07104500 | VKTX | Phase 3 | Active not recruiting | 2027-07-01Estimated |
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
Trial details
- Registry ID
- NCT04173065
- Phase
- Phase 2
VK2735 for Weight Management Phase 2
Trial details
- Registry ID
- NCT06068946
- Phase
- Phase 2
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Trial details
- Registry ID
- NCT06828055
- Phase
- Phase 2
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Trial details
- Registry ID
- NCT07104383
- Phase
- Phase 3
VK2735 for Weight Management Phase 3
Trial details
- Registry ID
- NCT07104500
- Phase
- Phase 3
Latest recorded trial changes
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383 · Viking Therapeutics, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Acute Hip Fracture Study in Patients 65 Years or Greater
NCT02578095 · Viking Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Efficacy in hip fracture patients confirmed by DXA scan.
+ After
Measure: Efficacy in Hip Fracture Patients Confirmed by DXA Scan.
VK2735 for Weight Management Phase 3
NCT07104500 · Viking Therapeutics, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
NCT06828055 · Viking Therapeutics, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Aug 2025
+ After
24 Jun 2025
Recruitment status changed
− Before
Recruiting
+ After
Completed